These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31383269)

  • 1. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.
    Abodakpi H; Wanger A; Tam VH
    Clin Lab Med; 2019 Sep; 39(3):473-485. PubMed ID: 31383269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tackling the Antibiotic Resistance Caused by Class A
    Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New promising β-lactamase inhibitors for clinical use.
    Olsen I
    Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three decades of beta-lactamase inhibitors.
    Drawz SM; Bonomo RA
    Clin Microbiol Rev; 2010 Jan; 23(1):160-201. PubMed ID: 20065329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host.
    Okereke C; Dudley MN
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():43-9. PubMed ID: 9688450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance.
    Silva ON; Franco OL; Porto WF
    Drugs Today (Barc); 2018 Dec; 54(12):737-746. PubMed ID: 30596392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.
    Crass RL; Pai MP
    Pharmacotherapy; 2019 Feb; 39(2):182-195. PubMed ID: 30589457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of beta-lactamase inhibitors].
    Hyodo A; Higashitani F; Nishida K; Kunugita C; Unemi N
    Nihon Rinsho; 1997 May; 55(5):1272-80. PubMed ID: 9155186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Lactamase inhibitors: what you really need to know.
    Ambrose PG; Lomovskaya O; Griffith DC; Dudley MN; VanScoy B
    Curr Opin Pharmacol; 2017 Oct; 36():86-93. PubMed ID: 29096172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on β-lactamase inhibitor discovery and development.
    Docquier JD; Mangani S
    Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
    Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactamase inhibitors: the story so far.
    Pérez-Llarena FJ; Bou G
    Curr Med Chem; 2009; 16(28):3740-65. PubMed ID: 19747143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing of inhibitors against CTX-M-15 type β-lactamase: potential drug candidate against β-lactamases-producing multi-drug-resistant bacteria.
    Ali A; Danishuddin ; Maryam L; Srivastava G; Sharma A; Khan AU
    J Biomol Struct Dyn; 2018 May; 36(7):1806-1821. PubMed ID: 28545327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.
    Bush LM; Johnson CC
    Infect Dis Clin North Am; 2000 Jun; 14(2):409-33, ix. PubMed ID: 10829263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.